7/27/2019 Farmako_Antimikroba rasional
1/32
Rational Antimicrobial
TherapyRianto Setiabudy
Department of Pharmacology FMUI Lecture for Infection and Immunology Module
April, 2010
1
7/27/2019 Farmako_Antimikroba rasional
2/32
Introduction (1)
The problems we are facing:The ever increasing problem of bacterialresistance (MRSA, VRE, ESBL producingpathogens, MDR hospital pathogens)Spread of infections in hospital setting
Cost of treatment Inappropriate use of antimicrobial agents
2
7/27/2019 Farmako_Antimikroba rasional
3/32
Introduction (2)
Lack of new antimicrobial agentsdeveloped in recent yearsUnnecessary financial burden to thepatientsScarcity of objective information onappropriate use of antimicrobial agents
3
7/27/2019 Farmako_Antimikroba rasional
4/32
Outlines (1)
Pharmacological factors affectingantimicrobial activitySelecting an appropriate antimicrobialagentUse of combinations
ProphylaxisDuration of antimicrobial treatment
4
7/27/2019 Farmako_Antimikroba rasional
5/32
Outlines (2)
Patterns of antimicrobial killingactivity
Penetration of antimicrobials intoCSFFactors responsible for treatment
failure
5
7/27/2019 Farmako_Antimikroba rasional
6/32
7/27/2019 Farmako_Antimikroba rasional
7/32
7/27/2019 Farmako_Antimikroba rasional
8/32
Selecting an antimicrobial agent (contd)
determine the drug of choice
give the drug
evaluate the result
stop or continue or modifythe treatment as necessary
If in appropriate give a second-line drug. Consider: safety,efficacy, suitability, and cost
8
7/27/2019 Farmako_Antimikroba rasional
9/32
Tips for selecting an appropriateantimicrobial agent (1)
If a sensitivity test indicates that a pathogen issensitive to some antibiotics, it does notmean all these agents have equal clinical
efficacyIf two or more antibiotics are equally safeand effective, choose the one with narrower antibacterial spectrumIn life- threatening condition a de -escalatingtherapy may be applied if the etiology isunknownGeneric antibiotics are not of low quality buttheir price is much more affordable
9
7/27/2019 Farmako_Antimikroba rasional
10/32
Tips for selecting an appripriateantimicrobial agent (2)
A new generation antibiotic is not alwayssuperior to its older generations
A slightly more potent antibiotic shown invitro, is not necessarily associated with better clinical efficacy
10
7/27/2019 Farmako_Antimikroba rasional
11/32
Use of antimicrobial combinations(1)
Indications:Empirical therapy of severe infections inwhich cause is unknownTreatment of polymicrobial infectionsEnhancement of antimicrobial activity in
treatment of specific infectionsPrevention of emergence of resistance
11
7/27/2019 Farmako_Antimikroba rasional
12/32
Use of antimicrobial combinations(2)
Examples of appropriate use of AM combinations:Septic shock due to Gram negative pathogens
Life-threatening infection of undetermined causeEnterococcal endocarditisSerious infections due to P. aeruginosa
Intra-abdominal infectionTuberculosis and leprosy treatment
12
7/27/2019 Farmako_Antimikroba rasional
13/32
Use of antimicrobial combinations(3)
Disadvantages of AM combinations:Increased risk of toxicity
Selection of multiple-drug-resistantmicroorganismsIncreased cost
Possibility of unexpected antagonisticeffect
13
7/27/2019 Farmako_Antimikroba rasional
14/32
Use of antimicrobial combinations(4)
Examples of possible clinical antagonisticeffect:Lepper & Dowling (Arch Int Med1951;88:489-94)Pneumococcal meningitis treated with:
Penicillin alone: fatality rate = 21% Penicillin + chlortetracycline: fatality rate =
79%
14
7/27/2019 Farmako_Antimikroba rasional
15/32
Prophylaxis
Characteristics of successful prophylaxis: Aimed at a specific pathogen The pathogen is highly sensitive to the
prophylactic agent used
Characteristics of unsuccessfulprophylaxis: Aimed at any or all microorganism in the
environment of a patient(Chambers, 2001)
15
7/27/2019 Farmako_Antimikroba rasional
16/32
Duration of therapy (1)
Determined by:The ability of the pathogens to resisthosts defense mechanism Physical location of the pathogenPotency of the AM agent
The frequency of development of resistance
16
7/27/2019 Farmako_Antimikroba rasional
17/32
Duration of therapy (2)
Examples: Acute uncomplicated cystitis: one dose 3days
Acute gonococcal urethritis: one dosePneumococcal pneumonia: until afebrile 3days, at least 5 daysBacterial endocarditis: 4 weeksStreptococcal pharyngitis: 10 daysPulmonary tuberculosis: 6 monthsExtra pulmonary tuberculosis: 12-24 months
17
7/27/2019 Farmako_Antimikroba rasional
18/32
Factors causing failure of treatment (1)
Poor antibacterial activity of a drugWrong route of administration or wrong dosageThe location of infection isinaccessible by the antimicrobialagent
Poor hosts defense mechanism Premature discontinuation of treatment
18
7/27/2019 Farmako_Antimikroba rasional
19/32
Factors causing failure of treatment (2)
Serious toxicity necessitatesdiscontinuation of therapy
Resistance of the microorganismSuperinfectionForeign body or necrotic tissues
Patients incompliance
19
7/27/2019 Farmako_Antimikroba rasional
20/32
Time-kill curves of P. aeruginosa with exposure to tobramycin
0
1
2
3
4
5
6
7
8
9
10
0 2 4 6
Control
1/4 MIC
1 MIC4 MIC
16 MIC
64 MIC
L o g
C F U / m l
Time (h)
(Craig, 1991) 20
7/27/2019 Farmako_Antimikroba rasional
21/32
Patterns of antibiotic killing activity(1)
Pattern 1: concentration-dependentkilling
E.g.: aminoglycosides,fluoroquinolones Strategy of dosing regimen:
maximize concentrations Parameters determining efficacy:ratios of Cmax/MIC or AUC/MIC
(Deziel-Evans, 1986)21
7/27/2019 Farmako_Antimikroba rasional
22/32
Time-kill curves of P. aeruginosa withexposure to ticarcillin
01
2
3
4
56
7
8
9
10
0 2 4 6 8
Control1/4 MIC1 MIC4 MIC16 MIC64 MIC
L o g
C F U / m
l
Time (h)(Craig, 1991)
22
7/27/2019 Farmako_Antimikroba rasional
23/32
Patterns of antibiotic killing activity(2)
Pattern 2: time-dependent killingE.g.: betalactams, macrolides,
oxazolidinedinones Strategy of dosing regimen: maximize
duration of exposure to antibiotics
Parameters determining efficacy:length of time of above-MIC antibioticblood level
23
7/27/2019 Farmako_Antimikroba rasional
24/32
Pharmacokinetic/Pharmaco-dynamic (PK/PD) parameters
For concentration-dependent killingpattern:
AUC/MIC (required: 125 and 30for Gram negative and Grampositive pathogens, respectively )
Cmax/MIC (required: 10)For time-dependent killing pattern: Time above MIC (required: 40%)
24
7/27/2019 Farmako_Antimikroba rasional
25/32
7/27/2019 Farmako_Antimikroba rasional
26/32
Penetration of antimicrobials into
cerebrospinal fluid (1)Excellent:
Trimethoprim
Sulfonamides Chloramphenicol INH Rifampicin Flucytocin
26
7/27/2019 Farmako_Antimikroba rasional
27/32
Penetration of antimicrobials intocerebrospinal fluid (2)
Good with inflammed meninges: Penicillin G Ampicillin Cloxacillin Ticarcillin Piperacillin
27
7/27/2019 Farmako_Antimikroba rasional
28/32
Penetration of antimicrobials intocerebrospinal fluid (3)
Ceftriaxone Ceftazidime Aztreonam Imipenem Fluoroquinolones
28
7/27/2019 Farmako_Antimikroba rasional
29/32
Penetration of antimicrobials intocerebrospinal fluid (4)
Poor penetration: Aminoglycosides
First generation cephalosporins Clindamycin Vancomycin Cefoxitin
29
7/27/2019 Farmako_Antimikroba rasional
30/32
Factors responsible for treatment
failure (1)Poor antimicrobial activity
Active antimicrobial agent fails to bedelivered to the site of infection insufficient concentrationInaccessible site of infection
Inadequate host body defensesTreatment duration is too short toprevent relapse
30
7/27/2019 Farmako_Antimikroba rasional
31/32
7/27/2019 Farmako_Antimikroba rasional
32/32
THANK YOU
32